Shares of CYBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Where can I buy Cybin shares?
May 11, 2022 · 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cybin stock. View analyst ratings for Cybin or view top-rated stocks.
What is the analyst rating for Cybin Inc (Cybin) stock?
May 06, 2021 · Forex.com. Cybin is a biotechnology business based in the US. Cybin stocks (CLXPF.US) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was $2.07 – the same closing value as a week prior. Cybin employs 38 staff and has a trailing 12-month revenue of around $864,000.
What is the upside for Cybin Inc (cybn) stock?
Apr 25, 2022 · 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cybin stock. View analyst ratings for Cybin or view top-rated stocks.
Is Cybin a profitable company?
You go to your online brokerage, look for Cybin. Common Shares stock, enter the number of shares you want to purchase, and then click buy. This will begin the transaction (also known as executing a buy order). Setting up a buy order is easy, too. You can choose from three options when placing an order: market, limit, and stop-loss.
Is Cybin a good investment?
Who owns Cybin stock?
...
New and Sold Out Positions.
| OWNER NAME | TCWP LLC |
|---|---|
| SHARES HELD | 68,500 |
| CHANGE (SHARES) | 68,500 |
| CHANGE (%) | New |
| VALUE (IN 1,000S) | $29 |
Is CYBN a buy?
The 8 analysts offering 12-month price forecasts for Cybin Inc have a median target of 6.77, with a high estimate of 10.00 and a low estimate of 0.79. The median estimate represents a +1,210.92% increase from the last price of 0.52.
Who is invested in Cybin?
| Holder | Shares | Value |
|---|---|---|
| Blackrock Inc. | 848,107 | 1,017,728 |
| AdvisorShares Investments, LLC | 583,184 | 699,820 |
| Penserra Capital Management LLC | 261,380 | 313,656 |
| Virtu Financial LLC | 105,547 | 126,656 |
Why is Cybin stock so low?
Does CYBN pay dividends?
Is Clxpf a buy?
What does Cybin Inc do?
Is CYBIN INC. (CYBN.NE) a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CYBIN INC. (CYBN.NE) in the last twelve months. There are currently 1 hold...
How were CYBIN INC. (CYBN.NE)'s earnings last quarter?
CYBIN INC. (CYBN.NE) (OTCMKTS:CYBN) posted its quarterly earnings data on Thursday, February, 10th. The company reported ($0.08) earnings per share...
What price target have analysts set for CYBN?
5 brokers have issued 12 month price objectives for CYBIN INC. (CYBN.NE)'s stock. Their forecasts range from $7.00 to $10.00. On average, they expe...
Who are CYBIN INC. (CYBN.NE)'s key executives?
CYBIN INC. (CYBN.NE)'s management team includes the following people: Eric So , Executive Chairman & President Douglas L. Drysdale , Chief Execu...
Who are some of CYBIN INC. (CYBN.NE)'s key competitors?
Some companies that are related to CYBIN INC. (CYBN.NE) include Ermenegildo Zegna (ZGN) , Equity Distribution Acquisition (EQD) , Vy Global Grow...
What is CYBIN INC. (CYBN.NE)'s stock symbol?
CYBIN INC. (CYBN.NE) trades on the OTCMKTS under the ticker symbol "CYBN."
Who are CYBIN INC. (CYBN.NE)'s major shareholders?
CYBIN INC. (CYBN.NE)'s stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (0.5...
Which institutional investors are selling CYBIN INC. (CYBN.NE) stock?
CYBN stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
Which institutional investors are buying CYBIN INC. (CYBN.NE) stock?
CYBN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., AdvisorShares Investments LLC, Cito...
Is Cybin a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cybin in the last twelve months. There are currently 4 buy ratings for the...
What price target have analysts set for CLXPF?
4 brokers have issued 12 month target prices for Cybin's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Cybin's stock...
Who are Cybin's key executives?
Cybin's management team includes the following people: Mr. Eric So L.L.B. , LLB, Co-Founder, Pres & Exec. Chairman (Age 45) Mr. Douglas L. Drysd...
Who are some of Cybin's key competitors?
Some companies that are related to Cybin include Accelerate Acquisition (AAQC) , Tech and Energy Transition (TETC) , North Atlantic Acquisition...
What is Cybin's stock symbol?
Cybin trades on the OTCMKTS under the ticker symbol "CLXPF."
How do I buy shares of Cybin?
Shares of CLXPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Cybin's stock price today?
One share of CLXPF stock can currently be purchased for approximately $0.82.
How much money does Cybin make?
Cybin has a market capitalization of $121.81 million and generates $680 thousand in revenue each year. The company earns $-24.42 million in net inc...
How many employees does Cybin have?
Cybin employs 6 workers across the globe.
Invest with CIBC Investor's Edge
Cybin is a biotechnology business based in the US. Cybin stocks (CLXPF.US) are listed on the OTCQB and all prices are listed in US Dollars. Its last market close was $2.07 – the same closing value as a week prior. Cybin employs 38 staff and has a trailing 12-month revenue of around $864,000.
How to buy shares in Cybin
Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Is it a good time to buy Cybin stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Have Cybin's shares ever split?
Cybin's shares were split on a 1:6 basis on 10 November 2020. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cybin shares – just the quantity.
Cybin share price volatility
Over the last 12 months, Cybin's shares have ranged in value from as little as $0.95 up to $3.38. A popular way to gauge a stock's volatility is its "beta".
Cybin overview
Cybin Inc. , a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U. S. , and Natures Journey. The Serenity Life and Cybin U. S.
What is Cybin Inc?
Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
What is the rating of Cybin?
Cybin has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Does Cybin pay dividends?
Cybin does not currently pay a dividend.
How to start investing in CYBN
The good news is that, unlike the old days, getting access to investment in stocks such as CYBN is very easy and can be done directly from your PC or even your smartphone. All you need is an internet connection and an investment plan in order to start buying Cybin. Common Shares stocks and shares.
Overview of Cybin. Common Shares (CYBN)
Cybin. Common Shares Company is a Worldwide company, traded on the Stock Market under the CYBN ticker. Cybin. Common Shares is a famous company in the Business Sector. Cybin. Common Shares has been involved in the Worldwide for many years, making it an attractive investment option.
Steps of buying Cybin. Common Shares stocks
So, for whatever reason, you’ve decided to invest in Cybin. Common Shares. That’s a solid start. Before you can officially state that you are an investor in Cybin. Common Shares, let’s take a look at what lies ahead of you! The procedure is similar for any stock and once again, we’re only using CYBN as an example.
What is a cybin?
Cybin ( NYSEMKT:CYBN) is developing medicinal psychedelic compounds, and as the name suggests, its lead program is based on psilocybin, the key active chemical in numerous species of "magic mushrooms." If you're an adventurous investor looking for a possible 10-bagger opportunity, this is one stock you shouldn't overlook, even if the therapies the company is developing might sound a bit unusual at first. Here are three reasons to consider adding it to your portfolio.
What is the Cybin platform?
In short, Cybin is developing a scanning device that can noninvasively measure the brain's responses to being under the influence of psychedelic chemicals.
Is psilocybin a psychotherapy?
Finally, on June 8 the company announced that it would be sponsoring a clinical trial examining the efficacy of psilocybin-assisted psychotherapy in healthcare workers who are experiencing depression, anxiety, and post-traumatic stress as a result of working on the front lines during the pandemic.
Does biotechnology sink or swim?
Biotechnology companies sink or swim depending on the strength of their technology platforms. In Cybin's case, there are three distinct platforms that matter: one for aiding in drug discovery and staking out intellectual property; another for calibrating drug dosing, optimal delivery, and controllability; and a third for measuring drug efficacy via brain scans of patients. There are a plethora of companies developing psychedelics that (broadly speaking) have platforms covering the first two areas. But Cybin's drug efficacy platform is, to my knowledge, unique in terms of its intended purpose as well as its value proposition.
Does Alex Carchidi have a position in any of the stocks mentioned?
Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
What is cybin neuroimaging?
Cybin is also an early mover in using neuroimaging techniques to generate data about how patients' brains behave before, during, and after treatment with psychedelics. That's a key capability, as it'll provide researchers with reams of quantitative data they can use to optimize treatment protocols or even the molecular makeup of the drugs. Furthermore, to my knowledge, no other psychedelics company has opted to make use of similar neuroimaging technology as extensively as Cybin plans to.
What is CYB 001?
The company is also planning to use an inhaler system that already has regulatory approval with CYB-004, a preclinical anxiety disorder treatment.
Is Cybin preparing for a takeoff?
Technology aside, several recent developments suggest that Cybin is preparing for a speedy takeoff .
Is Cybin a good stock to buy?
But if you're willing to take a calculated risk and make an investment in a psychedelics developer, Cybin is an excellent option, and people who buy it now could easily see their shares explode in value over time.
Is Cybin a biotech?
As favorable as Cybin's future appears to be, it's important to remember that it's a biotech stock that's deep in un charted waters. Nobody knows if or when the legality issues surrounding the company's psychedelic molecules will be resolved.
Does Alex Carchidi have a position in any of the stocks mentioned?
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Is Cybin a psychedelic drug?
For example, Cybin ( NYSEMKT:CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in "magic mushrooms"). Based on a swath of extremely positive coverage in the scientific literature, I'm of the opinion that these psychedelic therapies are going to be a tremendous force for good -- and investor returns -- over the coming years. And Cybin could well be one of the leaders in the psychedelics space, so let's take a look at why it's shaping up to be a brilliant investment.